Literature DB >> 29531159

Acetylation within the N- and C-Terminal Domains of Src Regulates Distinct Roles of STAT3-Mediated Tumorigenesis.

Chao Huang1,2, Zhe Zhang3, Lihan Chen2, Hank W Lee2, Marina K Ayrapetov4, Ting C Zhao4, Yimei Hao2, Jinsong Gao4, Chunzhang Yang5, Gautam U Mehta5, Zhengping Zhuang5, Xiaoren Zhang2, Guohong Hu2, Y Eugene Chin1,2.   

Abstract

Posttranslational modifications of mammalian c-Src N-terminal and C-terminal domains regulate distinct functions. Myristoylation of G2 controls its cell membrane association and phosphorylation of Y419/Y527 controls its activation or inactivation, respectively. We provide evidence that Src-cell membrane association-dissociation and catalytic activation-inactivation are both regulated by acetylation. In EGF-treated cells, CREB binding protein (CBP) acetylates an N-terminal lysine cluster (K5, K7, and K9) of c-Src to promote dissociation from the cell membrane. CBP also acetylates the C-terminal K401, K423, and K427 of c-Src to activate intrinsic kinase activity for STAT3 recruitment and activation. N-terminal domain phosphorylation (Y14, Y45, and Y68) of STAT3 by c-Src activates transcriptionally active dimers of STAT3. Moreover, acetyl-Src translocates into nuclei, where it forms the Src-STAT3 enhanceosome for gene regulation and cancer cell proliferation. Thus, c-Src acetylation in the N-terminal and C-terminal domains play distinct roles in Src activity and regulation.Significance: CBP-mediated acetylation of lysine clusters in both the N-terminal and C-terminal regions of c-Src provides additional levels of control over STAT3 transcriptional activity. Cancer Res; 78(11); 2825-38. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29531159     DOI: 10.1158/0008-5472.CAN-17-2314

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Cross-Talk between Wnt Signaling and Src Tyrosine Kinase.

Authors:  Jung Ki Min; Hwee-Seon Park; Yoon-Beom Lee; Jae-Gyu Kim; Jong-Il Kim; Jae-Bong Park
Journal:  Biomedicines       Date:  2022-05-11

2.  The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth.

Authors:  Fei-Fei Xu; Hui-Min Sun; Run-Ping Fang; Lu Zhang; Hui Shi; Xue Wang; Xue-Li Fu; Xian-Meng Li; Xu-He Shi; Yue Wu; Kai Ye; Wei-Ying Zhang; Li-Hong Ye
Journal:  Acta Pharmacol Sin       Date:  2021-04-06       Impact factor: 6.150

3.  Lycorine Displays Potent Antitumor Efficacy in Colon Carcinoma by Targeting STAT3.

Authors:  Song Wu; Yuling Qiu; Yingying Shao; Shuangshuang Yin; Rui Wang; Xu Pang; Junhong Ma; Chunze Zhang; Bo Wu; Sangho Koo; Lifeng Han; Yi Zhang; Xiumei Gao; Tao Wang; Haiyang Yu
Journal:  Front Pharmacol       Date:  2018-08-08       Impact factor: 5.810

Review 4.  Src Family Tyrosine Kinases in Intestinal Homeostasis, Regeneration and Tumorigenesis.

Authors:  Audrey Sirvent; Rudy Mevizou; Dana Naim; Marie Lafitte; Serge Roche
Journal:  Cancers (Basel)       Date:  2020-07-23       Impact factor: 6.639

5.  The regulation of acetylation and stability of HMGA2 via the HBXIP-activated Akt-PCAF pathway in promotion of esophageal squamous cell carcinoma growth.

Authors:  Yue Wu; Xue Wang; Feifei Xu; Lu Zhang; Tianjiao Wang; Xueli Fu; Tianzhi Jin; Weiying Zhang; Lihong Ye
Journal:  Nucleic Acids Res       Date:  2020-05-21       Impact factor: 16.971

Review 6.  Protein acetylation: a novel modus of obesity regulation.

Authors:  Yuexia Liu; Hong Yang; Xuanchen Liu; Huihui Gu; Yizhou Li; Chao Sun
Journal:  J Mol Med (Berl)       Date:  2021-06-01       Impact factor: 4.599

7.  CBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis.

Authors:  Chaohua Liu; Qiaoyan Yang; Qian Zhu; Xiaopeng Lu; Meiting Li; Tianyun Hou; Zhiming Li; Ming Tang; Yinglu Li; Hui Wang; Yang Yang; Haiying Wang; Ying Zhao; He Wen; Xiangyu Liu; Zebin Mao; Wei-Guo Zhu
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

Review 8.  STAT3 signaling in ovarian cancer: a potential therapeutic target.

Authors:  Renba Liang; Xishan Chen; Li Chen; Fangzhu Wan; Kaihua Chen; Yongchu Sun; Xiaodong Zhu
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.